Proof-of-Concept Study of the SNOEZELEN Device on Anxiety Symptoms in Patients Hospitalized for Chemotherapy in a Pediatric Oncology Department

Summary

The goal of this clinical trial is to evaluate whether the Snoezelen multisensory relaxation approach can reduce anxiety symptoms in children and adolescents aged 8 to 17 years hospitalized for chemotherapy in a pediatric oncology unit. Researchers will compare patients' symptoms during a chemotherapy cycle with Snoezelen sessions to a previous cycle without Snoezelen, in order to assess changes in psychological and physical well-being. Participants will: * Be enrolled between their first (without Snoezelen) and second (with Snoezelen) chemotherapy cycles * Complete self-report questionnaires on anxiety, depression, quality of life, and nausea * Receive 45-minute Snoezelen sessions every two days during their second hospitalization * Participate in a semi-structured interview after the final session * Provide data on medications (anxiolytics, antiemetics) and vomiting frequency during both hospitalizations

Eligibility

Inclusion Criteria:

* New patient
* Treated in the Paediatrics/AJA department of the Oscar Lambret Centre for cancer (all types of cancer)
* Hospitalisation for several days
* Highly emetogenic chemotherapy treatment: this corresponds to all in-patient treatments carried out in the Paediatrics/AJA department.
* Age at diagnosis : ≥ 8 years and \< 18 years.
* French language
* Information for the patient and those with parental authority; consent signed by the patient and those with parental authority.
* Valid social security cover

Exclusion Criteria:

* Contraindication to SNOEZELEN:

  * Claustrophobia
  * Presence of psychiatric, addictive or cognitive disorders that would prevent compliance with the protocol requirements;
* State of health not allowing participation in the study (severe fatigue, symptoms refractory to treatment).
* Pregnant or breast-feeding women

Conditions6

Browse More Trials